VVY.AS Stock - Vivoryon Therapeutics N.V.
Unlock GoAI Insights for VVY.AS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $-3,620,000 | N/A | $10.76M | N/A |
| Gross Profit | $-147,000 | $-3,095,000 | $-161,000 | $9.03M | $-146,000 |
| Gross Margin | N/A | 85.5% | N/A | 83.9% | N/A |
| Operating Income | $-20,961,000 | $-28,837,000 | $-29,132,000 | $-12,806,000 | $-16,017,000 |
| Net Income | $-20,568,000 | $-28,342,000 | $-28,156,000 | $-12,655,000 | $-16,510,000 |
| Net Margin | N/A | 782.9% | N/A | -117.6% | N/A |
| EPS | $-0.79 | $-1.12 | $-1.28 | $-0.63 | $-0.83 |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Visit WebsiteEarnings History & Surprises
VVY.ASEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 4, 2025 | — | $-0.21 | — | — |
Q2 2025 | Apr 29, 2025 | — | $-0.27 | — | — |
Q3 2024 | Sep 12, 2024 | — | $-0.52 | — | — |
Q2 2024 | May 23, 2024 | — | $-0.72 | — | — |
Q4 2023 | Dec 6, 2023 | — | $-0.41 | — | — |
Q2 2023 | May 16, 2023 | — | $-0.68 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.60 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.58 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.45 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.38 | — | — |
Q4 2019 | Dec 31, 2019 | $-0.66 | $-0.32 | +52.0% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | $-0.22 | $-0.30 | -40.1% | ✗ MISS |
Q4 2018 | Dec 31, 2018 | — | $-0.44 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.50 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.45 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.53 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-1.01 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.81 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-1.04 | — | — |
Latest News
Frequently Asked Questions about VVY.AS
What is VVY.AS's current stock price?
What is the analyst price target for VVY.AS?
What sector is Vivoryon Therapeutics N.V. in?
What is VVY.AS's market cap?
Does VVY.AS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VVY.AS for comparison